Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
The disparity is due to the greater prevalence of fibroids and nonendometrioid histologic type in Black women, according to researchers.
Hispanics have higher MM-related in-hospital mortality; recent decline seen in in-hospital mortality for all except NH-Blacks.
In the B-43 phase 3 trial, researchers did not achieve the objective of a 36% reduction in ipsilateral breast cancer rate with the addition of trastuzumab to radiotherapy.
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy showed no OS benefit compared with cytoreductive surgery in patients with colorectal peritoneal metastases.
Treatment-related toxicities were less likely with the lobaplatin-based regimen.
RSK4-targeting floxacins could boost the efficacy of chemotherapy.
Surgery was an independent predictor of overall survival.
Efficacy and toxicity outcomes were similar with calaspargase and pegaspargase.
Aspirin may prevent distant metastases, according to researchers.